{"id":"docetaxel-and-capecitabine-and-oxaliplatin","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Neutropenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"30-50","effect":"Nausea/vomiting"},{"rate":"30-50","effect":"Diarrhea"},{"rate":"10-30","effect":"Hand-foot syndrome"},{"rate":"20-40","effect":"Peripheral neuropathy"},{"rate":"40-60","effect":"Fatigue"},{"rate":"10-30","effect":"Mucositis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel is a taxane that prevents microtubule depolymerization, leading to cell cycle arrest. Capecitabine is a fluoropyrimidine prodrug that inhibits thymidylate synthase and gets incorporated into DNA/RNA. Oxaliplatin is a platinum agent that forms DNA adducts and interstrand crosslinks. Together, these three agents provide synergistic cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"This combination regimen uses three chemotherapy agents that work together to inhibit cancer cell division and survival through different mechanisms: docetaxel stabilizes microtubules, capecitabine inhibits thymidylate synthase, and oxaliplatin creates DNA crosslinks.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:41.127Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer (phase 3 investigation)"},{"name":"Potentially other solid tumors under investigation"}]},"trialDetails":[{"nctId":"NCT07069712","phase":"PHASE2","title":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-17","conditions":"Gastroesophageal Adenocarcinoma","enrollment":100},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT06123338","phase":"PHASE2","title":"A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-02-01","conditions":"Esophageal Cancer, Gastric Adenocarcinoma, HER2 Gene Mutation","enrollment":49},{"nctId":"NCT03801876","phase":"PHASE3","title":"Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2019-06-26","conditions":"Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8","enrollment":300},{"nctId":"NCT06741644","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2025-02-24","conditions":"Advanced Solid Tumors","enrollment":660},{"nctId":"NCT05836584","phase":"PHASE2","title":"Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-06","conditions":"Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8","enrollment":240},{"nctId":"NCT04615013","phase":"PHASE1","title":"NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-11-23","conditions":"Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8","enrollment":24},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT07098104","phase":"","title":"A Benefit Population Atlas of nICT Versus nCT for LAGC","status":"COMPLETED","sponsor":"Cheng Chen","startDate":"2019-11-01","conditions":"Gastric Cancer","enrollment":291},{"nctId":"NCT03448835","phase":"PHASE2","title":"Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2018-03-07","conditions":"Stomach Cancer, Gastro Esophageal Junction Cancer","enrollment":20},{"nctId":"NCT01924819","phase":"PHASE2, PHASE3","title":"Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2009-09","conditions":"Gastric Cancer","enrollment":574},{"nctId":"NCT05296005","phase":"PHASE1","title":"Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers","status":"WITHDRAWN","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2025-12-31","conditions":"Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8","enrollment":""},{"nctId":"NCT01876927","phase":"PHASE2","title":"Pre-Operative Or Peri-Operative Dox Regimen In Patients With Locally Advanced Resectable Gastric Cancer","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2010-09","conditions":"Gastric Cancer, Locally Advanced Malignant Neoplasm","enrollment":106},{"nctId":"NCT04276493","phase":"PHASE1, PHASE2","title":"Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab","status":"COMPLETED","sponsor":"BeiGene","startDate":"2020-03-26","conditions":"Breast Cancer, Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":71},{"nctId":"NCT02009449","phase":"PHASE1","title":"A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-11-15","conditions":"Melanoma, Prostate Cancer, Ovarian Cancer","enrollment":353},{"nctId":"NCT04937738","phase":"PHASE2","title":"Perioperative Chemotherapy in Gastric Cancer","status":"TERMINATED","sponsor":"Ukrainian Society of Clinical Oncology","startDate":"2021-07-21","conditions":"Gastric Cancer","enrollment":69},{"nctId":"NCT01404156","phase":"PHASE2, PHASE3","title":"Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Dr. Gordon Buduhan","startDate":"2015-09","conditions":"Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction","enrollment":29},{"nctId":"NCT06469060","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2024-06-19","conditions":"Esophageal Cancer","enrollment":34},{"nctId":"NCT06253650","phase":"PHASE2","title":"Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-03-01","conditions":"Gastric Cancer, HER2-positive Gastric Cancer","enrollment":46},{"nctId":"NCT02931890","phase":"PHASE2","title":"Multicentric Randomised Trial for Resectable Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2017-12-21","conditions":"Gastric Cancer","enrollment":207},{"nctId":"NCT02735239","phase":"PHASE1, PHASE2","title":"Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2016-06-24","conditions":"Esophageal Cancer","enrollment":73},{"nctId":"NCT01935778","phase":"PHASE3","title":"Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2013-10-02","conditions":"Gastric Cancer, Adjuvant Chemotherapy, XO","enrollment":286},{"nctId":"NCT06235164","phase":"","title":"The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer","status":"UNKNOWN","sponsor":"Fujian Medical University","startDate":"2019-01-01","conditions":"Locally Advanced Gastric Cancer","enrollment":585},{"nctId":"NCT03607656","phase":"PHASE2, PHASE3","title":"The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2018-06-08","conditions":"Gastric Cancer Stage IIIB, Gastric Cancer Stage IIIC","enrollment":270},{"nctId":"NCT05262335","phase":"PHASE2","title":"Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-12-01","conditions":"Gastrointestinal Tumors","enrollment":116},{"nctId":"NCT02555358","phase":"PHASE2","title":"Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Clinical Study","status":"COMPLETED","sponsor":"Qun Zhao","startDate":"2014-11","conditions":"Gastric Cancer","enrollment":300},{"nctId":"NCT05264896","phase":"PHASE3","title":"Perioperative FLOT vs Adjuvant XELOX for CA Stomach","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2022-03-21","conditions":"Cancer of Stomach, Adenocarcinoma","enrollment":110},{"nctId":"NCT01726452","phase":"PHASE3","title":"NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2013-01-24","conditions":"Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Oesophago-gastric Junction, Oesophageal Tumours","enrollment":377},{"nctId":"NCT05235542","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors","status":"UNKNOWN","sponsor":"Akeso","startDate":"2022-07-12","conditions":"Advanced Malignant Tumors","enrollment":130},{"nctId":"NCT00193128","phase":"PHASE1, PHASE2","title":"Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2004-04","conditions":"Esophagus Cancer","enrollment":59},{"nctId":"NCT02128243","phase":"PHASE2","title":"Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2014-09","conditions":"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma","enrollment":242},{"nctId":"NCT01359397","phase":"PHASE2","title":"Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer","status":"UNKNOWN","sponsor":"The Netherlands Cancer Institute","startDate":"2011-03","conditions":"Metastatic Gastric Cancer, Adenocarcinoma of the Gastro-oesophageal Junction","enrollment":""},{"nctId":"NCT01295086","phase":"NA","title":"Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2011-03","conditions":"Adenocarcinoma","enrollment":27},{"nctId":"NCT04351867","phase":"PHASE3","title":"A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer","status":"UNKNOWN","sponsor":"LiNing","startDate":"2020-09","conditions":"Stomach Neoplasms","enrollment":196},{"nctId":"NCT00446290","phase":"PHASE1","title":"Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2006-03","conditions":"Stomach Cancer","enrollment":22},{"nctId":"NCT02076594","phase":"PHASE3","title":"Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer","status":"TERMINATED","sponsor":"Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente","startDate":"2013-01","conditions":"Locally Advanced Unresectable Gastric Cancer, Metastatic Gastric Cancer","enrollment":171},{"nctId":"NCT02177552","phase":"PHASE2","title":"Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma","status":"UNKNOWN","sponsor":"Rigshospitalet, Denmark","startDate":"2014-06","conditions":"Esophageal Neoplasms, Stomach Neoplasms","enrollment":98},{"nctId":"NCT02358863","phase":"NA","title":"Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2015-02","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":13},{"nctId":"NCT00938470","phase":"PHASE2","title":"Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-01","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer","enrollment":73},{"nctId":"NCT03455205","phase":"NA","title":"Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Chemo Patients With Digestive Tract .","status":"UNKNOWN","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2017-12-24","conditions":"Digestive Tract","enrollment":270},{"nctId":"NCT00609336","phase":"PHASE2","title":"Perioperative Therapy for Resectable Pancreatic Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2008-01","conditions":"Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer","enrollment":35},{"nctId":"NCT01472250","phase":"","title":"A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China","status":"COMPLETED","sponsor":"Peking University","startDate":"2011-11","conditions":"Advanced Gastric Cancer","enrollment":498},{"nctId":"NCT00454636","phase":"PHASE2","title":"A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-03","conditions":"Gastric Cancer","enrollment":158},{"nctId":"NCT01558011","phase":"PHASE2","title":"Using Genetic Polymorphisms to Predict the Efficacy and Toxicity - A Gastric Adenocarcinoma Study","status":"TERMINATED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2012-03","conditions":"Gastric Adenocarcinoma","enrollment":51},{"nctId":"NCT00737438","phase":"PHASE2","title":"Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-08","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":22},{"nctId":"NCT01618474","phase":"PHASE2","title":"Trial of Adjuvant Chemotherapy for High Risk Gastric Cancer Patients","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2012-05","conditions":"Stomach Cancer","enrollment":100},{"nctId":"NCT02623153","phase":"PHASE2","title":"Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric Cancer","status":"UNKNOWN","sponsor":"Tianshu Liu","startDate":"2016-01","conditions":"Gastric Cancer","enrollment":200},{"nctId":"NCT01703910","phase":"PHASE2","title":"Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic","status":"COMPLETED","sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","startDate":"2012-11","conditions":"Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease","enrollment":29},{"nctId":"NCT02445209","phase":"PHASE3","title":"Comparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric Carcinoma","status":"COMPLETED","sponsor":"Jagiellonian University","startDate":"2010-09","conditions":"HER2 Negative Gastric Cancer","enrollment":56},{"nctId":"NCT01672333","phase":"PHASE2","title":"Response Rate and Side Effects of Preoperative Chemotherapy (TOX Regimen) in Patients With Locally Advanced Operable Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Milad Hospital","startDate":"2008-06","conditions":"Gastric Cancer","enrollment":50},{"nctId":"NCT01963702","phase":"PHASE2","title":"A Phase II Trial of Exploring the Predictive Factors of TX and XELOX Regimen in the First Line Treatment of MGC","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2012-08","conditions":"Gastric Cancer","enrollment":120},{"nctId":"NCT00511446","phase":"PHASE2","title":"Trial of Docetaxel, Oxaliplatin and Capecitabine (TEX) in Advanced or Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Martin-Luther-Universität Halle-Wittenberg","startDate":"2007-08","conditions":"Stomach Neoplasms","enrollment":56},{"nctId":"NCT00733616","phase":"PHASE2","title":"Efficacy and Safety Study of Combination Therapy With Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status","status":"COMPLETED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2008-11","conditions":"Gastric Cancer","enrollment":44},{"nctId":"NCT01710592","phase":"PHASE2","title":"A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2007-05","conditions":"Gastro Oesophageal Cancer","enrollment":35},{"nctId":"NCT00382720","phase":"PHASE2","title":"Docetaxel and Oxaliplatin in Gastric Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-09","conditions":"Stomach Neoplasms","enrollment":275},{"nctId":"NCT01053104","phase":"","title":"Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2009-11","conditions":"Metastatic Colorectal Cancer, Metastatic Breast Cancer","enrollment":26},{"nctId":"NCT01331928","phase":"PHASE2","title":"Sequential Chemotherapy With Xelox Follows by TX to Treat Gastric Cancer","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2011-01","conditions":"Gastric Cancer","enrollment":51}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["docetaxel/xeloda/oxliplatin"],"phase":"phase_3","status":"active","brandName":"Docetaxel and capecitabine and oxaliplatin","genericName":"Docetaxel and capecitabine and oxaliplatin","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination regimen uses three chemotherapy agents that work together to inhibit cancer cell division and survival through different mechanisms: docetaxel stabilizes microtubules, capecitabine inhibits thymidylate synthase, and oxaliplatin creates DNA crosslinks. Used for Gastric cancer (phase 3 investigation), Potentially other solid tumors under investigation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}